TG THERAPEUTICS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that TG THERAPEUTICS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $2.79M | Mar 1, 2023 |
| FY2022 | Dec 31, 2021 | $6.69M | Mar 1, 2023 |
| FY2022 | Dec 31, 2020 | $152.0K | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $152.0K | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $152.0K | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $152.0K | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $152.0K | Mar 1, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $616.29M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $329.00M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $233.66M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $2.79M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $6.69M | Feb 29, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $447.18M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $23.38M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $12.67M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | ($223.81M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | ($348.10M) | Feb 29, 2024 |
| FY2019 | Dec 31, 2019 | ($39.57M) | Mar 2, 2020 |
| FY2019 | Sep 30, 2019 | ($61.93M) | Mar 2, 2020 |
| FY2019 | Jun 30, 2019 | ($36.21M) | Mar 2, 2020 |
| FY2019 | Mar 31, 2019 | ($35.16M) | Mar 2, 2020 |
| FY2019 | Dec 31, 2018 | ($53.86M) | Mar 2, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $123.32M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $41.93M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $20.63M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | ($218.32M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | ($344.77M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($273.59M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | ($169.06M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | ($174.40M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | ($118.71M) | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | ($78.97M) | Mar 1, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $160.22M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $94.29M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $76.19M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $125.35M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $222.58M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $165.90M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $154.18M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $159.39M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $102.53M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $69.23M | Mar 1, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $232.03M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $154.30M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $122.71M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $95.48M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $128.09M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $107.85M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $15.03M | Mar 1, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($24.77M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($40.52M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | ($31.41M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | ($176.17M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | ($295.63M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($214.51M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | ($132.81M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | ($128.93M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | ($93.76M) | Mar 2, 2020 |
| FY2012 | Dec 31, 2012 | ($5.19M) | Mar 21, 2013 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $214.0K | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $45.0K | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $0 | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $14.0K | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $401.0K | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $357.0K | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $131.0K | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $90.0K | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $2.0K | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $344.0K | Mar 1, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.06B | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $577.69M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $329.59M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $193.57M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $379.63M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $625.64M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $163.01M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $83.62M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $97.38M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $54.78M | Mar 15, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $415.23M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $355.33M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $169.09M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $134.99M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $142.48M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $106.29M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $124.40M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $59.58M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $30.39M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $18.91M | Mar 15, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $648.02M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $222.36M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $160.50M | Feb 27, 2026 |
| FY2025 | Dec 31, 2022 | $58.59M | Feb 27, 2026 |
| FY2024 | Dec 31, 2021 | $237.15M | Mar 3, 2025 |
| FY2023 | Dec 31, 2020 | $519.35M | Feb 29, 2024 |
| FY2012 | Dec 31, 2012 | $15.55M | Mar 21, 2013 |
| FY2012 | Dec 31, 2011 | $9.62M | Mar 21, 2013 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $799.0K | Feb 29, 2024 |
| FY2023 | Dec 31, 2022 | $799.0K | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $799.0K | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $799.0K | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $799.0K | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $799.0K | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $799.0K | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $799.4K | Mar 15, 2018 |
| FY2016 | Dec 31, 2015 | $799.4K | Mar 16, 2017 |
| FY2015 | Dec 31, 2014 | $799.4K | Mar 15, 2016 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.08B) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($1.53B) | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | ($1.55B) | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | ($1.53B) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | ($1.33B) | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | ($980.60M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($701.22M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($528.35M) | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | ($354.86M) | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | ($236.39M) | Mar 15, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $79.15M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $179.89M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $92.93M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $102.30M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $298.89M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $553.44M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $112.64M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $41.96M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $56.72M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $25.03M | Mar 1, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $100.40M | Feb 29, 2024 |
| FY2022 | Dec 31, 2022 | $71.14M | Mar 1, 2023 |
| FY2022 | Dec 31, 2021 | $67.76M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $29.90M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $28.97M | Mar 1, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | (2) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Mar 1, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | (2) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Mar 1, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 155.31M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 155.84M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | 151.42M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | 146.39M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | 143.25M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | 140.58M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | 109.38M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | 83.87M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | 73.14M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | 56.78M | Mar 15, 2018 |